title: Iron-oxide labeling and outcome of transplanted mesenchymal stem cells in the infarcted myocardium.
abstract: BACKGROUND
  Cell labeling with superparamagnetic iron oxide (SPIO) nanoparticles enables noninvasive MRI and tracking of transplanted stem cells. We sought to determine whether mesenchymal stem cell (MSC) outcome is affected by SPIO labeling in a rat model of myocardial infarction.
  
  
  RESULTS
  Rat MSCs were labeled with SPIO (ferumoxides; Endorem; Guerbet, Villepinte, France). By trypan-blue exclusion assay, almost 100% of the cells remained viable after labeling. Seven days after MI, rats were randomized to injections of 2x10(6) SPIO-labeled MSCs, 2x10(6) unlabeled MSCs, or saline. Labeled cells were visualized in the infarcted myocardium as large black spots by serial MRI studies throughout the 4-week follow-up. The presence of labeled cells was confirmed by iron staining and real-time polymerase chain reaction on postmortem specimens. At 4 weeks after transplantation, the site of cell injection was infiltrated by inflammatory cells. Costaining for iron and ED1 (resident macrophage marker) showed that the iron-positive cells were cardiac macrophages. By real-time polymerase chain reaction, the Y-chromosome-specific SRY DNA of MSCs from male donors was not detected in infarcted hearts of female recipients. Serial echocardiography studies at baseline and 4 weeks after cell transplantation showed that both unlabeled and labeled MSCs attenuated progressive left ventricular dilatation and dysfunction compared with controls.
  
  
  CONCLUSIONS
  At 4 weeks after transplantation of SPIO-labeled MSCs, the transplanted cells are not present in the scar and the enhanced MRI signals arise from cardiac macrophages that engulfed the SPIO nanoparticles. However, both labeled and unlabeled cells attenuate left ventricular dilatation and dysfunction after myocardial infarction.
authors.affiliation: Neufeld Cardiac Research Institute, Sheba Medical Center, Tel-Hashomer 52621, Israel.
authors.forename: Yoram
authors.initials: Y
authors.lastname: Amsalem
authors.forename: Yael
authors.initials: Y
authors.lastname: Mardor
authors.forename: Micha S
authors.initials: MS
authors.lastname: Feinberg
authors.forename: Natalie
authors.initials: N
authors.lastname: Landa
authors.forename: Liron
authors.initials: L
authors.lastname: Miller
authors.forename: Dianne
authors.initials: D
authors.lastname: Daniels
authors.forename: Aharon
authors.initials: A
authors.lastname: Ocherashvilli
authors.forename: Radka
authors.initials: R
authors.lastname: Holbova
authors.forename: Orna
authors.initials: O
authors.lastname: Yosef
authors.forename: Israel M
authors.initials: IM
authors.lastname: Barbash
authors.forename: Jonathan
authors.initials: J
authors.lastname: Leor
mesh_terms: D000818:Animals; D004452:Echocardiography / Q000379:methods; D005290:Ferric Compounds / Q000032:analysis; D008280:Magnetics; D045164:Mesenchymal Stem Cell Transplantation / Q000379:methods*; D059630:Mesenchymal Stem Cells / Q000737:chemistry; D009203:Myocardial Infarction / Q000000981:diagnostic imaging / Q000601:surgery*; D009206:Myocardium / Q000737:chemistry / Q000473:pathology; D053758:Nanoparticles / Q000032:analysis; D011859:Radiography; D051381:Rats; D017207:Rats, Sprague-Dawley; D013194:Staining and Labeling / Q000379:methods*; D016896:Treatment Outcome; D020257:Ventricular Remodeling / Q000502:physiology
chemical_list: D005290:Ferric Compounds; C000499:ferric oxide